SCHEMBL21096375

SCHEMBL21096375

CC(C)(C)c1ccc(CC(=N)NO)cc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.46
HDAC8 Q9BY41 3/20 0.46
HDAC6 Q9UBN7 3/20 0.46
HDAC1 Q13547 1/20 0.46
NR1H4 Q96RI1 5/20 0.44
EPHX2 P34913 5/20 0.44
ALDH1A1 P00352 1/20 0.44
ESRRB O95718 1/20 0.43
ESRRG P62508 1/20 0.43
LMNA P02545 3/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NLRP3 Q96P20 1/20 0.41
TYR P14679 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL562722 0.81 HDAC1 (0.54) HDAC3HDAC8HDAC6HDAC1NLRP3
SCHEMBL1580990 0.78 IDO1 (0.44) HDAC6HDAC1ALDH1A1LMNASMN1; SMN2
SCHEMBL15581376 0.77 HDAC8 (0.58) HDAC3HDAC8HDAC6HDAC1NR1H4
SCHEMBL2700476 0.76 HTR1D (0.53) NR1H4EPHX2ALDH1A1ESRRBESRRG
SCHEMBL838150 0.75 CA2 (0.46) HDAC8ALDH1A1LMNA
SCHEMBL1965925 0.75 IDO1 (0.45) LMNASMN1; SMN2
SCHEMBL23578295 0.74 POLB (0.46) HDAC6ALDH1A1SMN1; SMN2NLRP3
SCHEMBL23578308 0.74 HDAC1 (0.38) HDAC3HDAC8HDAC6HDAC1ALDH1A1
SCHEMBL641405 0.74 IDO1 (0.44) HDAC3HDAC8HDAC6HDAC1ALDH1A1
SCHEMBL480288 0.74 CYP3A4 (0.35) HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 US disclosed
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 US disclosed
EP-4218785-A2 MITOCHONDRIA-TARGETING PEPTIDES Stealth BioTherapeutics Inc. (US) 2023-08-02 EP disclosed
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-05-11 US disclosed
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-05-11 US disclosed
EP-3723783-B1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC (US) 2023-02-15 EP disclosed
WO-2019118878-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS CORP. (MC) 2019-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795196-B2 Mitochondria-targeting peptides HSPE1, TFAM, TNNI3 HDAC3 3458/4885HDAC8 3351/4885HDAC6 2469/4885
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES HSPE1, TFAM, TNNI3 HDAC3 3458/4885HDAC8 3351/4885HDAC6 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.